In boys with DMD, executive skills such as self-control begin to lag around age 8, but show signs of partial catch-up by 14, ...

In research published in Developmental Medicine & Child Neurology, investigators have developed a brief, reliable, and valid ...

Commercial launch in Switzerland anticipated in H2 2026Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces ...

Solid Biosciences (SLDB) stock rises as a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy reaches ...

Shares of  Regenxbio rose Monday in premarket trading after the company said its treatment for Duchenne muscular dystrophy delivered positive trial results, strengthening the case for a speedier ...

Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.” ・Elevidys, a medicine intended for the ...

Duchenne muscular dystrophy (DMD) is a genetic condition that causes increasing muscle weakness over time. While DMD currently has no cure, researchers are studying potential new treatments. When ...

—Older age, presence of scoliosis, and other factors were associated with lower predicted forced vital capacity in patients with Duchenne muscular dystrophy using non-invasive ventilation. Individuals ...

PPMD extends its heartfelt thanks to all Race to End Duchenne runners, donors, and volunteers who made the 2026 Walt Disney World (R) Marathon Weekend a memorable and meaningful success. To learn more ...

Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 - Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissme ...